linagliptin, Tradjenta

April 13, 2015 − by Contributor − in Archived − Comments Off on linagliptin, Tradjenta

linagliptin, Tradjenta


Pharmacy Author:

Medical and Pharmacy Editor:

GENERIC NAME: linagliptin

BRAND NAME: Tradjenta

DRUG CLASS AND MECHANISM: Linagliptin is an oral drug that reduces blood
sugar (glucose) levels in patients with
type 2 diabetes. Linagliptin is a member
of a class of drugs that inhibit the enzyme, dipeptidyl peptidase-4 (DPP-4).
Other members of this class include sitagliptin (Januvia), and
saxagliptin
(Onglyza). Following a meal, incretin hormones such as glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released from
the intestine, and their levels increase in the blood. GLP-1 and GIP reduce
blood glucose by increasing the production and release of insulin from the
pancreas. GLP-1 also reduces blood glucose by reducing the secretion by the
pancreas of the hormone, glucagon, a hormone that increases the production of
glucose by the liver and raises the blood level of glucose. The net effect of
increased release of GLP-1 and GIP is to reduce blood glucose levels.
Linagliptin inhibits the enzyme, DPP-4, that destroys GLP-1 and GIP and thereby
increases the levels and activity of both hormones. As a result, levels of GLP-1
and GIP in the blood remain higher, and blood glucose levels fall. In summary,
linagliptin reduces blood glucose levels by inhibiting DPP-4 and increasing the
levels of GLP-1 and GIP. Linagliptin was approved by the FDA in May 2011.

PRESCRIBED FOR: Linagliptin is combined with diet and exercise to improve
blood glucose levels in patients with type 2 diabetes.

Medically Reviewed by a Doctor on 4/3/2015

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Back to Medications Index

Source:linagliptin, Tradjenta